Wechsler Adult Intelligence Scale, 3rd Edition (WAIS-III): Usefulness in the Early Detection of Alzheimer’s Disease

We examined Alzheimer’s disease (AD) patients using a Japanese version of the Wechsler Adult Intelligence Scale, 3rd Edition (JWAIS-III) to clarify i) the significance of expansion of the indicated age range, ii) the characteristics of cognitive impairment in AD patients and iii) the efficacy of th neuropsychological assessment for the early detection of AD using the Digit Symbol subtest, which involves attention and episodic memory, and the Pairing supplementa-ry test, which relates to digit symbol-incidental learning. The JWAIS-III was given to 43 AD patients (12 males and 31 females; mean age, 80.9 ± 6.3 years, who fulfilled the diagnostic cri-teria for AD on the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) and the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association. Severity of dementia of the patients was classified according to Functional Assessment Staging (F) as follows: 9 patients in F3 (borderline), 15 in F4 (mild AD), 12 in F5 (moderate AD), 7 in F6 (somewhat severe AD) and none in F7 (severe AD). i) Mean intelligence quotients (IQs) were: Full Scale IQ 84.3 ± 14.0, Verbal IQ 84.6 ± 12.5 and Performance IQ 86.9 ± 15.5. Comparison of IQs and subtest scores of the patients aged 75 years or older assessed by standard scores for 70 to 74 years of age, which is the upper limit of the indicated age range on the WAIS-R (the previous version of the WAIS-III), with those assessed by the standard scores for the appropriate age revealed that the former were significantly lower in IQ and all subtest scores. ii) Significant differ-ences were noted among the severities of dementia in the scores of 7 subtests for Similarities, Comprehension, Arithmetic, Digit Span, Letter-Number Sequencing, Digit Symbol and Sym-bol Search. iii) When both the Digit Symbol subtest scores of 7 points or more and the Digit Sumbol-Pairing supplementary test scores exceeding 10% of the cumulative percentile were regarded as normal, 11 of 15 (73.3%) patients in F4 (mild AD) could be detected. These find-ings suggest that i) expansion of the indicated age range in the WAIS-III allows a more valid assessment of cognitive function in AD patients, ii) a marked decline in abstract thinking and verbal problem-solving ability and relative preservation of Perceptual organization are char-acteristics of cognitive impairment in AD patients and iii) a combination of the Digit Symbol subtest with the Pairing supplementary test is useful for the early detection of AD

A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701

Background: The mainstream first-line chemotherapy for advanced/recurrent gastric cancer (ARGC) is combination therapy including platinum-based agents. With the progressive aging of the society, the incidence of gastric cancer in elderly patients is increasing. However, elderly patients cannot tolerate these agents because of renal dysfunction or low quality of life. The KSCC1701 study explored the efficacy and safety of S1 þ ramucirumab in elderly patients with ARGC. Patients and methods: Chemotherapy-naive patients aged 70 years with ARGC were eligible. Patients received S-1 (40e60 mg twice daily for 4 weeks in 6-week cycles) and ramucirumab (8 mg/kg every 2 weeks) until disease progression. The primary end-point was the 1-year overall survival (OS) rate. The anticipated lower threshold of 1-year survival was set at 40% in light of previous S-1ebased regimens. The secondary end-points included progression-free survival (PFS), OS, the overall response rate (ORR) and safety. Results: Between September 2017 and November 2019, 48 patients (34 men and 14 women) were enrolled in this study. The median patient age was 77.5 years, and all patients had a performance status of 0 (n Z 20) or 1 (n Z 28). The 1-year OS rate was 65.2%, which met the primary end-point. The median survival time and median PFS were 16.4 and 5.8 months, respectively. The ORR was 41.9%. The most frequent grade 3/4 (15%) adverse events were neutropenia, anorexia and anaemia. Conclusion: Considering these findings, S-1 þ ramucirumab appears to be an excellent treatment option for elderly patients with ARGC. (250 words). This trial has been registered with the Japan Registry of Clinical Trials Registry under the number jRCTs071180066.European Journal of Cancer, 166, pp.279-286; 202

Aspartate aminotransferase to alanine aminotransferase ratio is associated with frailty and mortality in older patients with heart failure

Abstract Frailty is a common comorbidity associated with adverse events in patients with heart failure, and early recognition is key to improving its management. We hypothesized that the AST to ALT ratio (AAR) could be a marker of frailty in patients with heart failure. Data from the FRAGILE-HF study were analyzed. A total of 1327 patients aged ≥ 65 years hospitalized with heart failure were categorized into three groups based on their AAR at discharge: low AAR (AAR < 1.16, n = 434); middle AAR (1.16 ≤ AAR < 1.70, n = 487); high AAR (AAR ≥ 1.70, n = 406). The primary endpoint was one-year mortality. The association between AAR and physical function was also assessed. High AAR was associated with lower short physical performance battery and shorter 6-min walk distance, and these associations were independent of age and sex. Logistic regression analysis revealed that high AAR was an independent marker of physical frailty after adjustment for age, sex and body mass index. During follow-up, all-cause death occurred in 161 patients. After adjusting for confounding factors, high AAR was associated with all-cause death (low AAR vs. high AAR, hazard ratio: 1.57, 95% confidence interval, 1.02–2.42; P = 0.040). In conclusion, AAR is a marker of frailty and prognostic for all-cause mortality in older patients with heart failure

Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction - The CIBIS-J Trial -

Background: The comparative tolerability, efficacy, and safety of bisoprolol and carvedilol have not been established in Japanese patients with heart failure and reduced ejection fraction (HFrEF). Methods and Results: The CIBIS-J trial is a multicenter, open-label, non-inferiority randomized controlled trial of bisoprolol vs. carvedilol in 217 patients with HFrEF (EF <= 40%). The primary endpoint was tolerability, defined as reaching and maintaining the maximum maintenance dose (bisoprolol 5 mg/day or carvedilol 20 mg/day) during 48 weeks of treatment. The primary endpoint was achieved in 41.4% of patients in bisoprolol (n=111) and 42.5% in carvedilol (n=106) groups. The non-inferiority of tolerability of bisoprolol compared with carvedilol was not supported, however, neither beta-blocker was superior with regard to tolerability. Heart rate (HR) decreased in both groups and its decrease from baseline was significantly greater in the bisoprolol group (20.3 vs. 15.4 beats/min at 24 week, P<0.05). Plasma B-type natriuretic peptide (BNP) levels decreased in both groups and the decrease was significantly greater in the carvedilol group (12.4 vs. 39.0 % at 24 weeks, P<0.05). Conclusions: There were no significant differences between bisoprolol and carvedilol in the tolerability of target doses in Japanese HFrEF patients. The clinical efficacy and safety were also similar despite the greater reduction in HR by bisoprolol and plasma BNP by carvedilol